文献速递肺外科

氯吡格雷围手术期行肺叶切除术患者的结局

Perioperative Outcomes of Patients Undergoing Lobectomy on Clopidogrel.
PubMed 文献 · Ann Thorac Surg · 2017-10-05

该研究回顾性分析2007至2015年接受肺叶切除术且围手术期使用氯吡格雷的62例患者,按停药时间分组(≤5天、6-14天、>14天),发现各组围手术期心血管或出血事件无显著差异。

要点

  • 氯吡格雷停药时间≤5天、6-14天或>14天组间围手术期结局无显著差异。
  • 总体输血率16%,主要心血管事件发生率6.5%。
  • 非ST段抬高型心肌梗死4例,其中3例有支架且均置入>1年。

核心结论

  • 各组围手术期心血管或出血事件无显著差异。
  • 氯吡格雷术前短期停药可能出血风险有限,术前停药>14天在适当选择患者中也可能安全。

研究设计与样本

  • 回顾性分析前瞻性机构数据库,纳入2007至2015年接受肺叶切除术且围手术期使用氯吡格雷的62例患者。
  • 按术前氯吡格雷停药时间分组:I组≤5天,II组6-14天,III组>14天。

主要发现

  • 氯吡格雷指征为冠心病44例(71%),其中35例(56%)有既往支架置入。
  • 总体输血率16%(10/62),主要心血管事件发生率6.5%(4/62)。
  • 非ST段抬高型心肌梗死4例,其中3例有支架且均置入>1年。
  • 估计失血量、手术时间和围手术期死亡在各组间无显著差异。

临床怎么用

  • 对于接受肺叶切除术的特定患者,氯吡格雷术前短期停药可能不显著增加出血风险。
  • 术前停用氯吡格雷>14天在适当选择患者中也可能安全。

局限性

  • 回顾性研究,样本量小(62例),可能存在选择偏倚。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Perioperative management of antiplatelet therapy for patients undergoing pulmonary resection must balance the risk of cardiovascular events with that of hemorrhage. An optimal approach has not been defined in this population. We sought to characterize outcomes of patients undergoing pulmonary lobectomy on antiplatelet therapy with clopidogrel. METHODS: A prospective institutional database was retrospectively reviewed to identify all patients undergoing pulmonary lobectomy from 2007 to 2015 who received perioperative clopidogrel. Patients were grouped according to the timing of clopidogrel discontinuation before operation: group I, 5 days or less; group II, 6 to 14 days; and group III, more than 14 days. Analyses were performed to assess the effect of timing of discontinuation on adverse events. RESULTS: Sixty-two patients were identified and included in the analysis. The indication for clopidogrel was coronary artery disease in 44 patients (71%), 35 (56%) of whom had prior stent placement. The overall incidences of transfusion and major cardiovascular events were 16% (10 of 62) and 6.5% (4 of 62), respectively. Non-ST elevation myocardial infarctions occurred in 4 patients. Three were in patients with stents, all placed more than 1 year before the operation. There were no significant differences identified in estimated blood loss, operative duration, or perioperative deaths. CONCLUSIONS: No significant outcome differences in perioperative cardiovascular or hemorrhagic events were identified among the groups. Although these findings suggest that clopidogrel may be discontinued shortly before the operation with limited risk of bleeding, we also found that holding therapy for more than 14 days preoperatively may be safe in appropriately selected patients.

来源:Ann Thorac Surg,查看原文。版权归原作者所有。

引用

  1. Atay SM, Correa AM, Hofstetter WL, et al. Perioperative Outcomes of Patients Undergoing Lobectomy on Clopidogrel. Ann Thorac Surg. 2017. PMID: 28987393. doi:10.1016/j.athoracsur.2017.05.021

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。